ProCE Banner Series

The Evolving Landscape in CLL/SLL: Application of Current Evidence and New Guideline Recommendations

Register now to attend either in-person or virtually for this 1.5-hour interactive satellite symposium held in conjunction with the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, to hear experts who serve on the National Comprehensive Cancer Network CLL/SLL panel discuss recent data and emerging treatment advances in the personalization of care of patients with CLL/SLL. After the symposium, view the on-demand webcast and download the associated slideset for use in your clinic.

To Register: Please click the green “Learn More” button below. On the next page, select either Register for In-Person Event or Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

For more information on ASCO’s Health and Safety policy for this event, please visit ASCO’s website.

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

Credits Available

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Registered Nurses: 1.50 Nursing contact hours

Physician Assistants: maximum of 1.50 hours of AAPA Category I (Preapproved) credits

Who Should Attend

This educational program is intended for oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with CLL/SLL.

All Events

The Evolving Landscape in CLL/SLL: Application of Current Evidence and New Guideline Recommendations

Past Events




ProCE Banner

7:00 PM - 8:30 PM Central Time (CT)

In-person | Virtual

Hilton Chicago, 720 South Michigan Avenue, Chicago, Illinois 60604


ProCE Banner Faculty
Jeremy S. Abramson, MD, MMSc

Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

ProCE Banner Faculty
Farrukh Awan, MD

Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Division of Hematology/Oncology
Harold C. Simmons Compreshensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

ProCE Banner Faculty
Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio


  • Welcome and Introduction
  • NCCN Guidelines review for first-line and second-line regimens
  • Key variables in decision making among treatment regimens
  • Class in Session: mastering the current regimen components
  • Strategies to optimize sequencing of therapies
  • Optimal management of treatment-related adverse events
  • Case-Based Panel Discussions
  • Spotlight of Key Abstracts at ASCO 2023
  • Treatment strategies on the horizon
  • Final Thoughts and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact prior to the live event.


Goal Statement
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL. 

Target Audience
This educational program is intended for oncologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with CLL/SLL. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL, taking into consideration the agent’s toxicity profile, prognostic variables, response to prior therapy, comorbidities, and patient preference
  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents with the similar molecular target used to treat CLL/SLL
  • Develop treatment plans to address unique clinical challenges, based on the available evidence and recommendations outlined in the NCCN Guidelines to optimize outcomes for patients with CLL/SLL
  • Evaluate the evolving role of measurable residual disease (MRD; often referred to as minimal residual disease), allogeneic hematopoietic cell transplant, and CAR T-cell therapy


Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.5 contact hours. 

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-23-030-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Attention Pharmacists:
You must complete the evaluation within 30 days of the activity for continuing pharmacy education credit to be reported to the CPE Monitor. Be sure to enter your NAPB e-profile ID and date of birth when prompted in the evaluation or your credit cannot be reported. If you have not already done so, please complete your e-profile at to obtain your NABP e-Profile ID.

Physician Assistants 

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. 

Disclosure of Conflicts of Interest 
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity.


Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca, BeiGene, and Lilly.

Supported by independent educational grants from Merck & Co., Inc., Rahway, NJ, USA, and Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.